ATE295354T1 - Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen - Google Patents

Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen

Info

Publication number
ATE295354T1
ATE295354T1 AT01957334T AT01957334T ATE295354T1 AT E295354 T1 ATE295354 T1 AT E295354T1 AT 01957334 T AT01957334 T AT 01957334T AT 01957334 T AT01957334 T AT 01957334T AT E295354 T1 ATE295354 T1 AT E295354T1
Authority
AT
Austria
Prior art keywords
hydroximino
fluorenes
heterocyclic
protein kinases
inhibiting protein
Prior art date
Application number
AT01957334T
Other languages
English (en)
Inventor
Wesley Kwan Mung Chong
Rohit Kumar Duvadie
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Application granted granted Critical
Publication of ATE295354T1 publication Critical patent/ATE295354T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
AT01957334T 2000-08-18 2001-07-31 Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen ATE295354T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22480500P 2000-08-18 2000-08-18
PCT/US2001/023897 WO2002016326A1 (en) 2000-08-18 2001-07-31 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases

Publications (1)

Publication Number Publication Date
ATE295354T1 true ATE295354T1 (de) 2005-05-15

Family

ID=22842288

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01957334T ATE295354T1 (de) 2000-08-18 2001-07-31 Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen

Country Status (16)

Country Link
US (1) US6462060B2 (de)
EP (1) EP1309563B1 (de)
JP (1) JP2004506720A (de)
AR (1) AR032891A1 (de)
AT (1) ATE295354T1 (de)
AU (1) AU2001279090A1 (de)
BR (1) BR0113258A (de)
CA (1) CA2411924A1 (de)
DE (1) DE60110802T2 (de)
ES (1) ES2238463T3 (de)
GT (1) GT200100170A (de)
MX (1) MXPA03001452A (de)
PA (1) PA8525701A1 (de)
PE (1) PE20020289A1 (de)
SV (1) SV2003000603A (de)
WO (1) WO2002016326A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770652B2 (en) * 2001-10-18 2004-08-03 Duquesne University Of The Holy Ghost Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
AU2002364051A1 (en) * 2002-01-24 2003-09-02 Children's Medical Center Corporation Anti-cancer combination and use thereof
PL1680140T3 (pl) * 2003-10-16 2011-11-30 Imclone Llc Inhibitory receptora-1 czynnika wzrostu fibroblastów i związane z nim sposoby leczenia
CN101068561A (zh) * 2004-10-06 2007-11-07 蒂尔坦制药有限公司 用于加强抗血管生成疗法的方法和组合物
RS51616B (en) 2005-03-29 2011-08-31 Icos Corporation HETEROARYL UREE DERIVATIVES USEFUL TO INHIBIT CHK1
WO2007026720A1 (ja) * 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. 縮環ピラゾール誘導体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
DE69532817T2 (de) 1994-11-10 2005-01-13 Millenium Pharmaceuticals, Inc., Cambridge Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US6514971B1 (en) 1996-03-15 2003-02-04 Zeneca Limited Cinnoline derivatives and use as medicine
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
DK0906268T3 (da) * 1996-05-30 2002-03-18 Aventis Pharma Inc Alkoxyaminosubstituerede fluorenoner og deres anvendelse som proteinkinase C-inhibitorer
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
BR9807305A (pt) 1997-02-05 2000-05-02 Warner Lambert Co Pirido [2,3-d] pirimidinas e 4-aminopirimidinas como inibidores de proliferação celular.
EP1017394B1 (de) 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin-abhängige-kinase inhibierende purinderivate
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DK1023063T3 (da) 1997-10-06 2004-01-26 Abbott Gmbh & Co Kg Indeno[1,2-c]-,naphtho[1,2-c]- og benzo[6,7]cyclohepta[1,2-c]pyrazolderivater
AP1445A (en) 1997-10-27 2005-07-10 Agouron Pharma Substituted 4-amino-thiazol-2-yl compounds as CDKs inhibitors.
WO1999030710A1 (en) 1997-12-13 1999-06-24 Bristol-Myers Squibb Company USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
AU748178B2 (en) 1998-02-26 2002-05-30 Aventis Holdings Inc. 6,9-disubstituted 2-(trans-(4- aminocyclohexyl) amino)purines
KR20010042868A (ko) 1998-04-21 2001-05-25 블레어 큐. 퍼거슨 항암제 및 증식 억제제로서의5-아미노인데노[1,2-ｃ]피라졸-4-온
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
EP1107958B1 (de) 1998-08-29 2006-08-16 AstraZeneca AB Pyrimidine verbindungen
JP2002523497A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
US6316603B1 (en) * 1998-09-08 2001-11-13 Agouron Pharmaceuticals, Inc. Modifications of the VEGF receptor-2 protein and methods of use
KR20010086005A (ko) * 1998-11-06 2001-09-07 스타르크, 카르크 트리사이클릭 피라졸 유도체

Also Published As

Publication number Publication date
PA8525701A1 (es) 2002-04-25
GT200100170A (es) 2002-05-16
WO2002016326A1 (en) 2002-02-28
EP1309563A1 (de) 2003-05-14
AR032891A1 (es) 2003-12-03
AU2001279090A1 (en) 2002-03-04
PE20020289A1 (es) 2002-05-27
JP2004506720A (ja) 2004-03-04
BR0113258A (pt) 2003-07-15
US6462060B2 (en) 2002-10-08
CA2411924A1 (en) 2002-02-28
DE60110802D1 (de) 2005-06-16
EP1309563B1 (de) 2005-05-11
ES2238463T3 (es) 2005-09-01
DE60110802T2 (de) 2005-10-06
SV2003000603A (es) 2003-01-13
MXPA03001452A (es) 2004-05-04
US20020049238A1 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
ATE288424T1 (de) Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
ATE269701T1 (de) Gyrase-inhibitoren und ihre verwendung
ATE533508T1 (de) Cripto-blockierende antikörper und ihre verwendung
ATE344246T1 (de) Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer
ATE522506T1 (de) 4-aminopicolinate und ihre verwendung als herbizide
ATE302193T1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
DE69824418D1 (de) Substituierte quinazolin-derivate und ihre verwendung als tyrosin-kinase inhibitoren
ATE394102T1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
ATE280163T1 (de) Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren
DE60044004D1 (de) Verwendung von Omega-Carboxyaryl-substituierten Diphenylharnstoffen als raf-Kinase-Inhibitoren
ATE456657T1 (de) Aromatische methyltransferasen und ihre verwendung
DE50102325D1 (de) Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one und ihre verwendung zur hemmung der hormonsensitiven lipase
DE60113283D1 (de) Thiadiazole und oxadiazole sowie ihre verwendung als phosphodiesterase-7 inhibitoren
ATE329906T1 (de) Substituierte 2-anilino-benzimidazole und ihre verwendung als nhe-inhibitoren
DE50212455D1 (de) Verwendung von Dimerdiolen
ATE419366T1 (de) Tyra-gene und ihre verwendung
DE50206094D1 (de) Substituierte isoindole und ihre verwendung
DE60101323D1 (de) Tricyclische proteinkinasehemmer
DE50106596D1 (de) Haftklebemasse und ihre verwendung
DE60322052D1 (de) N-acylaminoacetonitril-derivate und ihre verwendung zur kontrolle von parasiten
DE50008549D1 (de) Triazolotriazinone und ihre verwendung
DE60102151D1 (de) Neue thiochromanderivate und ihre verwendung als thrombininhibitoren
DE60116732D1 (de) Isothiazol-derivate und ihre verwendung als schädlingsbekämpfungsmittel
ATE295354T1 (de) Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties